cell-therapy-public-health-congress-2019-keynote

4 / 14

Note:
Page 15
April 15-16, 2019 | Milan, Italy
&
PUBLIC HEALTH,
EPIDEMIOLOGY AND NUTRITION
2nd World Congress on
CELL AND GENE THERAPY
2nd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Joint Event on
Cell and Gene Therapy 2019 & Public Health Congress 2019 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
A NOVEL LYMPHOABLATION
PRECONDITIONING AGENT (AVM0703)
VIA RECEPTOR MEDIATED INDUCTION
OF APOPTOSIS TO REDUCE PATIENT
TOXICITIES PRIOR TO CART THERAPY
OR STEM CELL TRANSPLANTS TO
REDUCE TOXICITIES AND IMPROVE
PATIENT SAFETY
C hemotherapy preconditioning prior to CART cells has been strong-
ly associated with CRS, neurotoxicity, patient death and in some
instances, has led to clinical trials being put on hold. There is an urgent
need to develop a non-toxic and safe agent that lympho-ablates similar
to chemotherapy. AVM0703 lympho-ablates both T and B lymphocytes
for‘immune reset’via receptor mediated induction of caspase dependent
apoptosis, sparing neutrophils, platelets, RBCs and stem cells. AVM0703
preconditioning will expand the number of patients eligible for CART
therapy to include those too frail to tolerate chemotherapy precondi-
tioning and will reduce the toxicities both medical and financial of che-
motherapy or biologics based lymphoablation. HSC based gene therapy
holds promise as a cure for many inherited primary immune deficiencies
such as sickle cell disease, cerebral adrenoleukodystrophy, cystinosis, epi-
dermolysis bullosa, hemophilia, enzyme replacements disorders, cystic fi-
brosis andmuscular dystrophies. The toxicities of required chemotherapy
preconditioning limit the number of people who choose HSCGT. A rela-
Theresa A Deisher, Arch Gen Intern Med 2019, Volume 3
DOI: 10.4066/2591-7951-C2-025
Theresa A Deisher obtained her PhD in Molecular
and Cellular Physiology from Stanford Universi-
ty School of Medicine, USA. She is an expert in
adult stem cell research and she is the first per-
son to discover adult pluripotent stem cells. She
is an inventor of over 35 issued US/Japan patents,
whose discoveries have led to clinical trials of fi-
broblast growth factor 18 for osteoarthritis and
cartilage repair and for Factor XIII for surgical
bleeding. Prior to founding AVM Biotechnology,
she worked at leading biotechnology companies
including Genentech, Repligen, ZymoGenetics,
Immunex and Amgen as their principal scientist
and R&DVice President. She had an extensive sci-
entific and management experience in the com-
mercial biotechnology field. She is a frequent lec-
turer on stem cell issues and an active member of
ASH (The American Society of Hematology) and
ASCO (American Society of Clinical Oncology).
Theresa A Deisher
AVM Biotechnology, USA
BIOGRAPHY